Oxidative Stress in DNA Repeat Expansion Disorders: A Focus on NRF2 Signaling Involvement

Overview

Journal Biomolecules

Publisher MDPI

Specialties Biochemistry
Molecular Biology

Date 2020 May 7

PMID 32369911

Citations 15

Authors

Piergiorgio La Rosa

Sara Petrillo

Enrico Silvio Bertini

Fiorella Piemonte

Affiliations

Soon will be listed here.

Abstract

DNA repeat expansion disorders are a group of neuromuscular and neurodegenerative diseases that arise from the inheritance of long tracts of nucleotide repetitions, located in the regulatory region, introns, or inside the coding sequence of a gene. Although loss of protein expression and/or the gain of function of its transcribed mRNA or translated product represent the major pathogenic effect of these pathologies, mitochondrial dysfunction and imbalance in redox homeostasis are reported as common features in these disorders, deeply affecting their severity and progression. In this review, we examine the role that the redox imbalance plays in the pathological mechanisms of DNA expansion disorders and the recent advances on antioxidant treatments, particularly focusing on the expression and the activity of the transcription factor NRF2, the main cellular regulator of the antioxidant response.

Citing Articles

A Novel Class of FKBP12 Ligands Rescues Premature Aging Phenotypes Associated with Myotonic Dystrophy Type 1.

Garcia-Puga M, Gerenu G, Bargiela A, Espinosa-Espinosa J, Mosqueira-Martin L, Sagartzazu-Aizpurua M Cells. 2024; 13(23).

PMID: 39682688 PMC: 11639790. DOI: 10.3390/cells13231939.

Genome-wide identification and expression analysis of the OSC gene family in .

Wang X, Yan D, Chen L PeerJ. 2024; 12:e18322.

PMID: 39677956 PMC: 11639181. DOI: 10.7717/peerj.18322.

Mitochondrial dysfunction in Fragile X syndrome and Fragile X-associated tremor/ataxia syndrome: prospect use of antioxidants and mitochondrial nutrients.

Pagano G, Lyakhovich A, Pallardo F, Tiano L, Zatterale A, Trifuoggi M Mol Biol Rep. 2024; 51(1):480.

PMID: 38578387 PMC: 10997711. DOI: 10.1007/s11033-024-09415-7.

The impact of physical activity on promoter-specific methylation of genes involved in the redox-status and disease progression: A longitudinal study on post-surgery female breast cancer patients undergoing medical treatment.

Moulton C, Murri A, Benotti G, Fantini C, Duranti G, Ceci R Redox Biol. 2024; 70:103033.

PMID: 38211440 PMC: 10821067. DOI: 10.1016/j.redox.2024.103033.

Vitamin B12 Deficiency and the Nervous System: Beyond Metabolic Decompensation-Comparing Biological Models and Gaining New Insights into Molecular and Cellular Mechanisms.

Mathew A, Di Matteo G, La Rosa P, Barbati S, Mannina L, Moreno S Int J Mol Sci. 2024; 25(1).

PMID: 38203763 PMC: 10778862. DOI: 10.3390/ijms25010590.

References

Bott L, Badders N, Chen K, Harmison G, Bautista E, Shih C . A small-molecule Nrf1 and Nrf2 activator mitigates polyglutamine toxicity in spinal and bulbar muscular atrophy. Hum Mol Genet. 2016; 25(10):1979-1989. PMC: 5062587. DOI: 10.1093/hmg/ddw073. View

Tassone F, Iwahashi C, Hagerman P . FMR1 RNA within the intranuclear inclusions of fragile X-associated tremor/ataxia syndrome (FXTAS). RNA Biol. 2006; 1(2):103-5. DOI: 10.4161/rna.1.2.1035. View

Cotticelli M, Crabbe A, Wilson R, Shchepinov M . Insights into the role of oxidative stress in the pathology of Friedreich ataxia using peroxidation resistant polyunsaturated fatty acids. Redox Biol. 2014; 1:398-404. PMC: 4802835. DOI: 10.1016/j.redox.2013.06.004. View

Day J, Ricker K, Jacobsen J, Rasmussen L, Dick K, Kress W . Myotonic dystrophy type 2: molecular, diagnostic and clinical spectrum. Neurology. 2003; 60(4):657-64. DOI: 10.1212/01.wnl.0000054481.84978.f9. View

Jiraanont P, Kumar M, Tang H, Espinal G, Hagerman P, Hagerman R . Size and methylation mosaicism in males with Fragile X syndrome. Expert Rev Mol Diagn. 2017; 17(11):1023-1032. PMC: 5924764. DOI: 10.1080/14737159.2017.1377612. View

Koeppen A . Friedreich's ataxia: pathology, pathogenesis, and molecular genetics. J Neurol Sci. 2011; 303(1-2):1-12. PMC: 3062632. DOI: 10.1016/j.jns.2011.01.010. View

Dejager S, Bry-Gauillard H, Bruckert E, Eymard B, Salachas F, Leguern E . A comprehensive endocrine description of Kennedy's disease revealing androgen insensitivity linked to CAG repeat length. J Clin Endocrinol Metab. 2002; 87(8):3893-901. DOI: 10.1210/jcem.87.8.8780. View

Liguori I, Russo G, Curcio F, Bulli G, Aran L, Della-Morte D . Oxidative stress, aging, and diseases. Clin Interv Aging. 2018; 13:757-772. PMC: 5927356. DOI: 10.2147/CIA.S158513. View

Jang M, Choi J, Chang Y, Lee S, Nah S, Cho I . Gintonin, a ginseng-derived ingredient, as a novel therapeutic strategy for Huntington's disease: Activation of the Nrf2 pathway through lysophosphatidic acid receptors. Brain Behav Immun. 2019; 80:146-162. DOI: 10.1016/j.bbi.2019.03.001. View

10.

Johnson W, Wilson-Delfosse A, Mieyal J . Dysregulation of glutathione homeostasis in neurodegenerative diseases. Nutrients. 2012; 4(10):1399-440. PMC: 3497002. DOI: 10.3390/nu4101399. View

11.

Rawdin B, Mellon S, Dhabhar F, Epel E, Puterman E, Su Y . Dysregulated relationship of inflammation and oxidative stress in major depression. Brain Behav Immun. 2012; 31:143-52. PMC: 3669232. DOI: 10.1016/j.bbi.2012.11.011. View

12.

Yao W, Zhang J, Ishima T, Ren Q, Yang C, Dong C . Antidepressant effects of TBE-31 and MCE-1, the novel Nrf2 activators, in an inflammation model of depression. Eur J Pharmacol. 2016; 793:21-27. DOI: 10.1016/j.ejphar.2016.10.037. View

13.

Huber K, Gallagher S, Warren S, Bear M . Altered synaptic plasticity in a mouse model of fragile X mental retardation. Proc Natl Acad Sci U S A. 2002; 99(11):7746-50. PMC: 124340. DOI: 10.1073/pnas.122205699. View

14.

Paulson H . Repeat expansion diseases. Handb Clin Neurol. 2018; 147:105-123. PMC: 6485936. DOI: 10.1016/B978-0-444-63233-3.00009-9. View

15.

Sofola O, Jin P, Qin Y, Duan R, Liu H, de Haro M . RNA-binding proteins hnRNP A2/B1 and CUGBP1 suppress fragile X CGG premutation repeat-induced neurodegeneration in a Drosophila model of FXTAS. Neuron. 2007; 55(4):565-71. PMC: 2215388. DOI: 10.1016/j.neuron.2007.07.021. View

16.

Koriyama Y, Chiba K, Yamazaki M, Suzuki H, Muramoto K, Kato S . Long-acting genipin derivative protects retinal ganglion cells from oxidative stress models in vitro and in vivo through the Nrf2/antioxidant response element signaling pathway. J Neurochem. 2010; 115(1):79-91. DOI: 10.1111/j.1471-4159.2010.06903.x. View

17.

Kensler T, Wakabayashi N, Biswal S . Cell survival responses to environmental stresses via the Keap1-Nrf2-ARE pathway. Annu Rev Pharmacol Toxicol. 2006; 47:89-116. DOI: 10.1146/annurev.pharmtox.46.120604.141046. View

18.

Sidorov M, Auerbach B, Bear M . Fragile X mental retardation protein and synaptic plasticity. Mol Brain. 2013; 6:15. PMC: 3636002. DOI: 10.1186/1756-6606-6-15. View

19.

Tanaka T, Terada M, Ariyoshi K, Morimoto K . Monocyte chemoattractant protein-1/CC chemokine ligand 2 enhances apoptotic cell removal by macrophages through Rac1 activation. Biochem Biophys Res Commun. 2010; 399(4):677-82. DOI: 10.1016/j.bbrc.2010.07.141. View

20.

Liu Y, Lu Y, Celiku O, Li A, Wu Q, Zhou Y . Targeting IDH1-Mutated Malignancies with NRF2 Blockade. J Natl Cancer Inst. 2019; 111(10):1033-1041. PMC: 6792082. DOI: 10.1093/jnci/djy230. View